Table 3.
Characteristics of three patients experiencing first VT episode during follow-up
| Patient #1 | Patient #2 | Patient #3 | |
|---|---|---|---|
| Demographics | |||
| Sex | M | M | M |
| Age at time of diagnosis (years) | 55 | 69 | 59 |
| Proband | Yes | Yes | Yes |
| Pathogenic mutation | – | – | + (PKP2) |
| Sustained arrhythmia characteristics | |||
| Age at time of arrhythmia | 55 | 71 | 59 |
| Morphology | LBBB | LBBB | LBBB |
| Axis | Superior | Superior | Inferior |
| Cycle length (ms) | 240 | 231 | 429 |
| Documentation | Walking | Cardiac stress test | Holter monitoring |
| Clinical phenotype at time of sustained arrhythmia | |||
| Repolarisation TFC | None | None | TWI V1–4 (major) |
| Depolarisation TFC | None | Late potentials (minor) | Epsilon wave (major) |
| Arrhythmia TFC | LBBB superior axis VT (major) | 560 PVCs/24 h (minor), LBBB superior axis VT (major) | 11180 PVCs/24 h (minor), LBBB inferior axis VT (minor) |
| Structural TFC | RV aneurysm + reduced RV function (major) | RV aneurysm + reduced RV function (major) | RV aneurysm + reduced RV function (major) |
| Family history TFC | None | None | Major |
| TFC points at time of arrhythmic event | 4 | 5 | 8 |
| Clinical features | |||
| Symptoms prior to event | Exercise-induced syncope, presyncope | Palpitations | Palpitations |
| Medication at time of arrhythmia | Perindopril 8 mg, Hydrochlorothiazide 25 mg | Atenolol 25 mg | Acenocoumarola, Enalapril 20 mg, Simvastatin 40 mg |
| Relevant comorbidity | Hypertension | – | Ischaemic CVA |
| Coronary angiography | Normal | Normal | Normal |
CVA cerebrovascular accident, LBBB left bundle branch block, PKP2 Plakophilin-2, PVC premature ventricular complex, TFC Task Force Criteria, TWI T-wave inversion, VT ventricular tachycardia
a Indication for acenocoumarol was a history of ischaemic CVA